HER2 Antibody

CD340; NEU; HER-2; HER-2/neu; ERBB2; MLN 19; NGL; TKR1; erb-b2 receptor tyrosine kinase 2; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2

This antibody has been successfully used to immunoprecipitate p185 erbB-2 protein from human SKBR3 breast tumor cell lysates and human erbB-2-transfected mouse HCll R111 cells. Furthermore, the binding of this antibody to surface-expressed HER2 on SKBR3 cells was determined using flow cytometry. Treatment with this antibody led to a rapid increase in the phosphotyrosine content of the erbB-2 protein in various cell lines. The binding of this antibody stimulated the turnover of the erbB-2 protein but did not stimulate DNA synthesis in HCll R111 cells. Therefore, it can be inferred that this antibody acts as a partial ligand agonist (Harwerth et al., 1992; PMID: 1353079) . The binding affinity of this antibody for human HER2 was determined using ELISA (Wels et al., 1992; PMID: 1369487) . The scFv version of this antibody was used in the generation of scFv (FRP5) -ETA, an antibody-exotoxin recombinant protein and tested for its anti-tumor activity (Harwerth et al., 1993; PMID: 7903153) . ScFv (FRP5) -ETA displayed potent antitumoral activity in vitro against a wide range of established and primary human tumor cells, including breast and ovarian carcinomas, squamous cell carcinomas and prostate carcinomas. scFv (FRP5) -ETA also effectively inhibited the in vivo growth of human tumor xenografts and murine and rat tumor cells stably transfected with human c-erbB2 constructs (von Minckwitz et al., 2005; PMID: 16168106) .